
Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Global Forecast 2024-2030
Description
Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Global Forecast 2024-2030
The Ulcerative Colitis Market size was estimated at USD 7.45 billion in 2023 and expected to reach USD 8.14 billion in 2024, at a CAGR 9.41% to reach USD 13.99 billion by 2030.
Global Ulcerative Colitis Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Ulcerative Colitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ulcerative Colitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Ulcerative Colitis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi SA.
Market Segmentation & Coverage
This research report categorizes the Ulcerative Colitis Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug
Anti-Inflammatory Drugs
Anti-TNF Biologics
Calcineurin Inhibitors
Immunosuppressant
Disease
Fulminant Colitis
Left-Sided Colitis
Pancolitis or Universal Colitis
Proctosigmoiditis
Ulcerative Proctitis
Route of Administration
Injectable
Oral
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Ulcerative Colitis Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ulcerative Colitis Market?
3. What are the technology trends and regulatory frameworks in the Ulcerative Colitis Market?
4. What is the market share of the leading vendors in the Ulcerative Colitis Market?
5. Which modes and strategic moves are suitable for entering the Ulcerative Colitis Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Ulcerative Colitis Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidence of ulcerative colitis globally
- 5.1.1.2. Robust availability of healthcare facilities and evolving drug development sector
- 5.1.1.3. Availability of patient assistance programs and reimbursement policies
- 5.1.2. Restraints
- 5.1.2.1. Fluctuating cost of raw materials
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing research and development in the production of novel drugs
- 5.1.3.2. Increasing public and private organization involvement in research of biologics
- 5.1.4. Challenges
- 5.1.4.1. Strict government mandates in approval of biosimilars
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Ulcerative Colitis Market, by Drug
- 6.1. Introduction
- 6.2. Anti-Inflammatory Drugs
- 6.3. Anti-TNF Biologics
- 6.4. Calcineurin Inhibitors
- 6.5. Immunosuppressant
- 7. Ulcerative Colitis Market, by Disease
- 7.1. Introduction
- 7.2. Fulminant Colitis
- 7.3. Left-Sided Colitis
- 7.4. Pancolitis or Universal Colitis
- 7.5. Proctosigmoiditis
- 7.6. Ulcerative Proctitis
- 8. Ulcerative Colitis Market, by Route of Administration
- 8.1. Introduction
- 8.2. Injectable
- 8.3. Oral
- 9. Americas Ulcerative Colitis Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Ulcerative Colitis Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Ulcerative Colitis Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. AbbVie Inc.
- 13.1.3. AstraZeneca PLC
- 13.1.4. Bausch Health Companies Inc.
- 13.1.5. BioLineRx Ltd
- 13.1.6. Boehringer Ingelheim GmbH
- 13.1.7. Celgene Corporation
- 13.1.8. Circle33, LLC
- 13.1.9. Cosmo Pharmaceuticals NV
- 13.1.10. Eli Lilly and Company
- 13.1.11. GlaxoSmithKline Plc
- 13.1.12. Johnson & Johnson Services, Inc.
- 13.1.13. Merck & Co., Inc.
- 13.1.14. Mitsubishi Tanabe Pharma Corporation
- 13.1.15. Pfizer Inc.
- 13.1.16. Sanofi SA
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ULCERATIVE COLITIS MARKET RESEARCH PROCESS
- FIGURE 2. ULCERATIVE COLITIS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ULCERATIVE COLITIS MARKET DYNAMICS
- FIGURE 7. ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
- FIGURE 8. ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
- FIGURE 10. ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 12. ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.